Ticker

Orocidin's QR-01 demonstrates efficacy in two preclinical periodontitis models; micro-CT confirms reduced bone loss Phase IIa clinical trial in patients planned H1 2027 at the University of Copenhagen Bio-Convert receives toxicity waiver from Danish Medicines Agency; GMP manufacturing on track for December 2026 NoviThera establishes biological proof of concept for QR-04 in psoriasis Uplisting application remains…

BEVERLY HILLS, California, June 15, 2026 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a biotech company specializing in developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders, is pleased to provide a corporate update, highlighting an overview of developments in its subsidiaries, Oricidin, Bio-Convert and NoviThera, and…